_edited_edited.png)
Brooks Hill Partners has invested in Cellbricks, a Berlin-based startup leveraging a novel suite of 3D bioprinting technologies to transform preclinical pharmaceutical research and clinical care. Cellbricks will soon enter preclinical trials for its 3D bioprinted personalized post-mastectomy breast reconstruction implant.
Learn more about Cellbricks here.